Update on cancer therapeutics最新文献_第2页

TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality TROG 96.01: TTBF和PSAdt作为疾病特异性死亡率的替代指标

Update on cancer therapeutics Pub Date : 2009-05-01 DOI: 10.1016/j.uct.2009.03.001

Christopher J. Hoimes, William Kevin Kelly

引用次数: 0

Copyright 版权

Update on cancer therapeutics Pub Date : 2009-05-01 DOI: 10.1016/S1872-115X(09)00022-X

引用次数: 0

The MET axis as a therapeutic target MET轴作为治疗靶点

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/j.uct.2009.01.001

Martin Sattler , Ravi Salgia

{"title":"The MET axis as a therapeutic target","authors":"Martin Sattler , Ravi Salgia","doi":"10.1016/j.uct.2009.01.001","DOIUrl":"10.1016/j.uct.2009.01.001","url":null,"abstract":"<div><p>The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) have been implicated in transformation of a variety of malignancies. Chronic or dysregulated activation of the MET/HGF pathway may lead to increased cell growth, invasion, angiogenesis, and metastasis, reduced apoptosis, altered cytoskeletal functions and other biological changes. It has been suggested that ligand activated MET stimulation can be sufficient for a transforming phenotype. In addition, amplification and activation mutations (germline and/or somatic) within the tyrosine kinase domain, juxtamembrane domain, or semaphorin domain have been identified for MET. MET gain-of-function mutations lead to either deregulated or prolonged tyrosine kinase activity, which are instrumental to its transforming activity. A number of therapeutic strategies targeting ligand-dependent activation or the kinase domain have been employed to inhibit MET. The different structural requirements for activation of signaling events and biological functions regulated by MET will be summarized. Therapeutic targets and current pre-clinical and clinical approaches will be described. Targeting the HGF/MET pathway, alone or in combination with standard therapies, is likely to improve present therapies in MET-dependent malignancies.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2009.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28903329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36

Systemic therapy and novel agents for metastatic castration resistant prostate cancer 转移性去势抵抗性前列腺癌的全身治疗和新药物

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/j.uct.2008.10.002

Mark T. Fleming , Guru Sonpavde , G. Varuni Kondagunta , Matthew D. Galsky , Thomas E. Hutson , Cora N. Sternberg

引用次数: 3

Biological abbreviations 生物的缩写

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/S1872-115X(09)00012-7

引用次数: 0

Abbreviations of chemotherapeutic combinations 化疗联合的缩写

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/S1872-115X(09)00011-5

引用次数: 0

Abbreviations of drugs 药物简写

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/S1872-115X(09)00010-3

引用次数: 0

NSC-numbers NSC 号码

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/S1872-115X(09)00013-9

引用次数: 0

Development of novel agents for ovarian cancer 卵巢癌新药的研究进展

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/j.uct.2009.02.001

B.T. Hennessy, M. Markman

{"title":"Development of novel agents for ovarian cancer","authors":"B.T. Hennessy, M. Markman","doi":"10.1016/j.uct.2009.02.001","DOIUrl":"10.1016/j.uct.2009.02.001","url":null,"abstract":"<div><p>Epithelial ovarian cancer, the fourth leading cause of cancer deaths in American women, is a devastating disease. Although the combined intraperitoneal and intravenous administration of first-line chemotherapy does produce some improvement in patient outcomes in comparison with intravenous administration alone, the results of completed clinical trials suggest that a plateau has been reached in the benefits that can be achieved with cytotoxic chemotherapy alone in ovarian cancer. Epithelial ovarian cancer is currently classified by surgical and histologic criteria. However, the predictive value of this classification is limited. Moreover, the complexity of the different subtypes of ovarian cancer presents challenges to our understanding of the origin and pathogenesis of this disease. The sequential acquisition of molecular anomalies as occurs in colorectal carcinogenesis has not been described for ovarian cancer. However, increasing evidence indicates that multiple genetic and epigenetic events contribute to epithelial ovarian carcinogenesis. These events include aberrations in the expression of patterning genes, genomic instability, and resultant chromosomal changes, and may be triggered by excessive exposure of surface epithelial cells to autocrine/paracrine stimulation by sex steroids and other growth factors. As the disease progresses, activation of kinase pathways and continued abnormal autocrine/paracrine stimulation contribute to genomic instability and chemoresistance but also identify novel potential targets for therapeutic intervention. Although the list of genomic and other aberrations in ovarian cancer is daunting, a systems approach and the integration of therapies targeting multiple component ‘driver’ genes of important genetic aberrations has potential in treatment and for potentiation of cytotoxic chemotherapy efficacy.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2009.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55739408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

News Round - Up 新闻汇总

Update on cancer therapeutics Pub Date : 2009-04-01 DOI: 10.1016/j.uct.2009.03.004

引用次数: 0